Claudin-1 in Head and Neck Squamous Cell Carcinoma
Oncology · 2024
DOI: 10.1159/000540775 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Oncology, 2024. Verfasst von Stefano Cavalieri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoma, Squamous Cell, Claudin-1, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The objective response rate to immunotherapy is limited in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients, whose prognosis is still dismal. Few prognostic factors are clinically available, mostly related to patient or disease characteristics. Gene expression signatures offer better prognostic abilities but are mainly used in research. One such GE model classifies HNSCC into 6 clusters with different prognoses. Claudin-1 (CLDN1), which influences tumor microenvironment and immune cell infiltration, has emerged as a potential target, especially in cancers like HNSCC with high CLDN1 expression.
Methods
A single-center cohort of 100 loco-regionally advanced HNSCC patients from the BD2Decide observational study was analyzed. Patients were selected to balance long-term survivors and deceased patients, including HPV-negative and HPV-positive cases. Primary tumor specimens underwent GE analysis using Affymetrix ClariomD chips. Primary endpoint was overall survival (OS).
Results
The cohort comprised 100 HNSCC patients with a median age of 60 years, predominantly men (76%). Median OS and disease-free survival (DFS) were 94.24 and 42.79 months, respectively. CLDN1 expression varied significantly among primary sites, being highest in hypopharynx cancers. Differences in expression were not significant when stratified by HPV status or clinical stage. CLDN1 expression differed across the 6 transcriptomic clusters, with the highest levels in clusters associated with mesenchymal and hypoxic features. Higher CLDN1 expression correlated with shorter OS (hazard ratio [HR]: 3, p = 0.0023) and DFS (HR: 2.14, p = 0.02).
Conclusion
CLDN1 expression is heterogeneous in HNSCC and carries prognostic significance. It is highest in tumors with HPV-like biology and hypoxic environments, and lowest in immune-sensitive clusters. High CLDN1 is a negative prognostic factor and a promising therapeutic target. Anti-CLDN1 treatments could improve outcomes of CLDN1+ HNSCC patients, and combination therapies with ICIs might overcome resistance in CLDN1− cases. These findings support the need for clinical studies on anti-CLDN1 therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
- Integrated Biology of Rare Tumors, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Zitieren
APA
Cavalieri, S., Bergamini, C., Lenoci, D., Ottini, A., Lucchetta, M., Torchia, E., Licitra, L., & De Cecco, L. (2024). Claudin-1 in Head and Neck Squamous Cell Carcinoma. Oncology. https://doi.org/10.1159/000540775
Vancouver
Cavalieri S, Bergamini C, Lenoci D, Ottini A, Lucchetta M, Torchia E, et al. Claudin-1 in Head and Neck Squamous Cell Carcinoma. Oncology. 2024. doi:10.1159/000540775
BibTeX
@article{Cavalieri2024,
author = {Cavalieri, Stefano and Bergamini, Cristiana and Lenoci, Deborah and Ottini, Arianna and Lucchetta, Marta and Torchia, Erica and Licitra, Lisa and De Cecco, Loris},
title = {Claudin-1 in Head and Neck Squamous Cell Carcinoma},
journal = {Oncology},
year = {2024},
doi = {10.1159/000540775}
}
EUVIMED